CNCAV revealed today that in Europe a new type of vaccine produced by Johnson & Johnson is subject to the authorization procedure, and it is estimated that somewhere around mid-March it could receive approval for use.
Until now, various studies have placed the effectiveness of the Johnson&Johnson vaccine below that of those from Pfizer, Moderna, or AstraZeneca, so it remains to be seen what the European Medicines Agency will decide about it and its use in Europe.
"The Johnson & Johnson vaccine could be authorized in the first part of March
The European Medicines Agency (EMA) has received the application for conditional marketing authorization for the Johnson & Johnson/Janssen vaccine.
What's next?
The EMA will carry out an independent and in-depth scientific evaluation of the vaccine.
Based on the EMA assessment, if the vaccine is proven to be safe and effective, the European Commission will move quickly to grant a marketing authorization in the EU.
The vaccine can then be used in EU member states.
To speed up the assessment process, EMA reviewed data from Johnson & Johnson / Janssen Pharmaceuticals on an ongoing basis as they became available.
EMA experts could issue an opinion by mid-March 2021, provided the company's data on the vaccine's efficacy, safety and quality are sufficiently comprehensive and robust.
Two other vaccine manufacturers, CureVac and Novavax, are currently submitting data for ongoing review.”
